Reeves v. Eli Lilly and Co.

368 F. Supp. 2d 11, 2005 U.S. Dist. LEXIS 3957, 2005 WL 599973
CourtDistrict Court, District of Columbia
DecidedMarch 11, 2005
DocketCiv.A. 03-00237 (RCL)
StatusPublished
Cited by8 cases

This text of 368 F. Supp. 2d 11 (Reeves v. Eli Lilly and Co.) is published on Counsel Stack Legal Research, covering District Court, District of Columbia primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Reeves v. Eli Lilly and Co., 368 F. Supp. 2d 11, 2005 U.S. Dist. LEXIS 3957, 2005 WL 599973 (D.D.C. 2005).

Opinion

MEMORANDUM OPINION

LAMBERTH, District Judge.

This matter comes before the court on defendant’s motion for summary judgment. Upon consideration of the parties’ filings, the applicable law and the facts of this case, this Memorandum Opinion finds that the defendant’s motion for summary judgment should be DENIED and that a genuine issue of material fact exists as to the statute of limitations on the plaintiffs discovery of her injury caused by defendant’s product.

I. Introduction

Plaintiff Tammy Lynn Reeves brings a products liability action against defendant Eli Lilly and Company asserting five counts for -negligence, strict, liability, breach of warranty, misrepresentation, and punitive damages. Specifically, she alleges exposure in utero on or about 1970-1971 to the prescription drug diethyl- *12 stilbestrol (DES). As a result of plaintiffs exposure to DES in útero, she allegedly suffered injuries, including, but not limited to, uterine and cervical malformations with resulting infertility as well as physical and mental pain. Plaintiff Tammy L. Reeves Complaint (“Complaint”), No. 3, 4. Defendant Lilly manufactured, sold, and distributed DES nationwide. 1 This lawsuit was filed on January 17, 2003.

II. Background

For over three decades, doctors prescribed diethylstilbestrol to nearly five million women in the United States as a way to prevent pregnancy problems such as miscarriage. According to the St. Louis Post-Dispatch of April 3, 1997, “it was called a wonder drug when first developed 60 years ago.” 2 But the synthetic estrogen also known as DES didn’t work. Instead, according to several news articles published locally and nationally, “DES was linked to reproductive problems and cancers in daughters and abnormalities in some sons of women who took the drug” so reported the Florida Times-Union citing the National Cancer Institute. 3

Doctors stopped prescribing DES, “after the discovery of a rare reproductive tract tumor in teenage daughters of women who had taken the drug” reported the Patriot Ledger in 1999. 4 Research conducted in 1971 “linked in útero DES exposure to an unusual vaginal and cervical cancer” called clear cell adenocarcinoma (CCA), “showing up in young women” reported the Atlanta Journal-Constitution in 2003. 5 Although the drug was banned, for pregnancy in 1971 and the “pharmaceutical [company] Eli Lilly removed ... DES from the mar *13 ket in the summer of 1997,” according to the newsletter “People’s Medical Society” published in 1997, 6 “there are fears a third generation of DES babies will be affected” so reported the Sun-Sentinel in 1999. 7 The Florida Times-Union reported in 1999 that, “the National Cancer Institute says there currently is no evidence that grandchildren of women who took DES have higher health risks.” 8

Although there are current medical studies underway to determine a link between initial DES exposure in daughters and to a third generation of female grandchildren, “decades of study on DES have revealed as many as 1 in 1,000 DES daughters may develop CCA, the vaginal/cervieal cancer, and that their ability to become pregnant and sustain pregnancies may be impaired,” so reported the Atlanta Journal-Constitution. 9 There is a 30 percent risk of breast cancer among mothers who took the drug and making this a complicated issue is the fact that no medical test exists to detect DES exposure, according to this same news article. Because “few clues exist to help anyone figure out whether they are part of the DES generation” the Atlanta Journal-Constitution reported in 2003 that the Centers for Disease Control and prevention spent $1 million in a national public awareness and information campaign “in the hopes of alerting or reminding mothers and their offspring born between 1938 and 1971 of possible health risks.” 10

On or about 1970 and 1971, plaintiffs mother allegedly bought and ingested DES while living in Illinois. Prior to birth, plaintiffs mother took the drug prescribed by her doctor during pregnancy. Plaintiffs mother had been given large amounts of DES following twelve pregnancy losses. The plaintiff states defendant Lilly manufactured the DES she was exposed to in útero. Tammy L. Bennett was born in Illinois on February 26, 1971. (Complaint, No. 3 and Defendant Memorandum, No. 2).

Plaintiff first became aware that her mother took DES during pregnancy in the fall of 1987. 11 At age 16, Tammy Lynn Bennett consulted an Obstetrician & Gynecologist located in Delaware, Ohio complaining of pelvic pain for several months, progressively getting worse. By the time the plaintiff came to visit' Dr. Carolyn Hix-son, plaintiff had a history of an “inflamed colon” diagnosed by Barium Enema. 12 She had also suffered from kidney inflammation, having been examined by an exploratory laparoscopy revealing “scar tissue” in her abdomen. 13 Dr. Hixson notes in her diagnosis that plaintiffs medical history is noteworthy because her mother *14 took DES during pregnancy, pointing out both her mother and aunt had breast cancer. 14

Dr. Hixson performed several exams on the plaintiff in October of 1987, including breast, abdominal, pelvic, and cervix exams. Although the breast, abdominal, and pelvic, exams were diagnosed as normal, Dr. Hixson stated to Dr. Robert Caulkins, who appears to be plaintiffs family doctor at. the time, that “the cervix did show extensive adenosis covering the ecto cervix which would be consistent with the history of DES exposure.” 15 As Dr. Hixson found, “no specific abnormalities were detected which would have contributed to her pain.” 16 At that time, Dr. Hixson referred plaintiff to Dr. Grant Schmidt, who was an infertility and endocrinology specialist who had a special interest in DES patients. The importance of seeing such a specialist was out of future concerns, “particularly when [Tammy L. Bennett] becomes desirous of pregnancy.” 17 Meanwhile, Dr. Hix-son treated the pelvic pain conservatively, placing plaintiff on birth control pills and a nonsteroidal antiflammatory agent Motrin.

Several months later, Dr. Schmidt reported back to Dr. Hixson that he had examined the plaintiff referred for antenatal DES exposure. 18 Along with her mother, Dr.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Kubicki v. Medtronic, Inc.
District of Columbia, 2018
Kubicki ex rel. Kubicki v. Medtronic, Inc.
293 F. Supp. 3d 129 (D.C. Circuit, 2018)
Kiwanuka v. Bakilana
District of Columbia, 2012
Kiwanuka v. Bakilana
844 F. Supp. 2d 107 (D.C. Circuit, 2012)
Bergbauer v. Mabus
810 F. Supp. 2d 251 (District of Columbia, 2011)
Gaudreau v. American Promotional Events, Inc.
511 F. Supp. 2d 152 (District of Columbia, 2007)
American Registry of Pathology v. Ohio Casualty Insurance
461 F. Supp. 2d 61 (District of Columbia, 2006)
Gassmann v. Eli Lilly and Co.
407 F. Supp. 2d 203 (District of Columbia, 2005)

Cite This Page — Counsel Stack

Bluebook (online)
368 F. Supp. 2d 11, 2005 U.S. Dist. LEXIS 3957, 2005 WL 599973, Counsel Stack Legal Research, https://law.counselstack.com/opinion/reeves-v-eli-lilly-and-co-dcd-2005.